Cyclerion Therapeutics Inc

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC stimulators, a small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate (cGMP). The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.

Bionano Genomics

DermTech Inc

Aldeyra Therapeutics

Sol-Gel Technologies

Cyclerion Therapeutics, Inc. (NASDAQ: CYCN), Sol-Gel Technologies Ltd. (NASDAQ: SLGL), Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), DermTech, Inc. (NASDAQ: DMTK) and Bionano Genomics, Inc. (NASDAQ: BNGO) are among the biggest health care movers Tuesday.

Why Cyclerion, Sol-Gel, Aldeyra, DermTech and Bionano Genomics Are Moving Today

Provided updates on development strategy and execution for CY6463, a first-in-class, CNS-penetrant sGC stimulator, including IND clearance from FDA in ADv and ongoing MELAS program

Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress

The stock price of Cyclerion Therapeutics Inc (NASDAQ: CYCN) increased by over 3% pre-market. This is why it happened.

CYCN Stock: Over 3% Increase Pre-Market Explanation

Senior CNS expert and biotech business leader to inform strategy and future clinical development Senior CNS expert and biotech business leader to inform strategy and future clinical development

Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors

Aptinyx Inc

Bioline RX

Lineage Cell Therapeutics Inc

Palatin Technologies

5 Penny Stocks To Watch For The Last Week Of April 2021 The post Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week

CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that Cheryl Gault, Chief Operating Officer will present a corporate overview at B. Riley's Neuroscience Investor Conference on Thursday, April 29, 2021 at 1:00 p.m. ET.   Cyclerion leaders will also be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through B. Riley.

Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference

Company to discuss clinical updates for CY6463, including Phase 2a studies in ADv and MELAS, and plans to initiate Phase 1b clinical trial in CIAS

Cyclerion Therapeutics to Host Pipeline Update Webinar

CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that Christopher Wright, M.D., Ph.D., Chief Medical Officer, has resigned his position with the company. He will provide Cyclerion with transitional support until March 26, 2021 and will join the Company's Clinical Advisory Board.

Cyclerion Therapeutics Announces Departure of Chief Medical Officer

The stock price of Cyclerion Therapeutics Inc (NASDAQ: CYCN) is trading at over 25% today as of 3:28 PM ET. This is why it happened.

CYCN Stock Price Increases Over 25%: Why It Happened

Leading experts in central nervous system (CNS) clinical development and translational sciences to advise company's advancement of therapeutic pipeline candidates

Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing innovative medicines for people with serious diseases of the central nervous system (CNS), today announced that it will present a corporate overview at upcoming investor conferences:

Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C.

Anjeza Gjino promoted to Chief Financial Officer; Bill Huyett to transition to Strategic Advisor

Cyclerion Announces Leadership Transitions

Positive IW-6463 translational pharmacology study in healthy elderly subjects showed significant i mprovements in multiple measures associated with age-related cognitive decline and neurodegenerative diseases

Cyclerion Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Updates

A second midstage failure is hurting the biotech's stock price today.

Why Cyclerion Therapeutics Is Crashing Today

Study results do not support further internal development Study results do not support further internal development

Cyclerion Announces Phase 2 STRONG-SCD Study Results in Patients with Sickle Cell Disease

Showed significant i mprovements in neurophysiological and objective performance measures associated with age-related cognitive decline and neurodegenerative diseases

Cyclerion Announces Positive Data from IW-6463 CNS Translational Pharmacology Study in Healthy Elderly Subjects

CAMBRIDGE, Mass., Sept.  04, 2020  (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that Company management will be participating in several upcoming September 2020 investor conferences:

Cyclerion to Participate at Upcoming September 2020 Investor Conferences

CAMBRIDGE, Mass., Aug.  25, 2020  (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases, today announced that it has been awarded a grant from the Alzheimer's Association’s Part the Cloud-Gates Partnership Grant Program. This award will support the Company’s upcoming Phase 2 trial of IW-6463 in Alzheimer’s Disease with vascular pathology (ADv). The award provides Cyclerion with $2 million of funding over the next 2 years.

Cyclerion Announces Translational Research Award from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program

-  IW-6463 and olinciguat top line clinical study results remain on track for late summer and late Q3 2020, respectively    -

Cyclerion Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights

 -  Additional capital to accelerate clinical development of IW-6463 in two CNS indications and olinciguat for sickle cell disease  -

Cyclerion Therapeutics Completes $24 Million Private Placement

CAMBRIDGE, Mass., July  17, 2020  (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases, today announced that Christopher Winrow, Ph.D., Senior Director, Neuroscience Development Program Lead, presented on “Leveraging Biomarker Data & Preclinical Models to Guide the Design of Clinical Studies” at the Annual Biomarkers in Alzheimer’s Disease Summit that was held virtually on July 15, 2020.

Cyclerion Therapeutics Presentation at Biomarkers in Alzheimer’s Disease Summit

– Closed enrollment for olinciguat Phase 2 STRONG SCD study for sickle cell disease; topline data readout expected  Q3 2020 –

Cyclerion Updates Corporate Progress

– Management to review the Company's sGC clinical pipeline programs: praliciguat for diabetic nephropathy, olinciguat for sickle cell disease, and IW-6463 for neurodegenerative diseases –

Cyclerion to Present at the J.P. Morgan Healthcare Conference

The company evaluated praliciguat in 2 diseases, diabetic nephropathy and HFpEF, which are very complex and difficult-to-treat.

Cyclerion Therapeutics Trading Near Cash; Offers A Favorable Risk Reward Opportunity

A double clinical trial failure sends the biotech’s shares down.

News for Cyclerion Therapeutics Inc Stock (CYCN)